Figure 2.

Scheme representing the circle (continuous loop) of adaptive precision cancer medicine. For newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients, after collection of patient material specific tumor profiles acquired by several high-throughput technologies together with risk stratification will guide precision therapeutic strategies. When patients are confronted with refractory or relapsed DLBCL disease, tumor profiling and risk stratification will be redone, resulting in redirection of the original therapeutic approaches. As DLBCL is an evolutionary genetic disease, this procedure can be repeatedly used to serially repress the lymphoma in view of specific evolved subclones, thereby optimizing PM at every disease stage of the patient.